Trial reportBMC cancer2025
Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma.
Trial report in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Concurrent versus sequential immune checkpoint inhibition in the neoadjuvant treatment of resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis.Clinical and translational radiation oncology · 2027Review
- Neoadjuvant Chemoimmunotherapy versus Chemoradiotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis.Annals of surgical oncology · 2026Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundThe efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy have been presented and evaluated in previously published TD-NICE study. However, the long-term impacts of patients who received tislelizumab plus chemotherapy followed by surgery were not observed in the study.
methodsFrom September 2020 to March 2021, a total of 45 patients were enrolled in the TD-NICE trial. The 4 -year follow-up data of the TD-NICE ITT population were collected by investigators. The primary endpoint was OS, and the secondary endpoint was EFS. Kaplan-Meier method and cox proportional hazards model were used to proceed statistical analysis.
resultsThe median OS and EFS were not reached in all patients. The OS was 82.2% (95%CI:67.6-90.7) at 12 months, 73.3%(95%CI:57.8-83.9) at 24 months, 66.7%(95%CI:50.9-78.4) at 36 months and simulated 66.2% (95%CI:46.5-74.6) at 48 months. There were statistically significant differences between surgery and non-surgery patients(P = 0.046). And patients with R0 resection had a higher improvement in OS than those with R1&R2 resection (P = 0.041). The differences in EFS in surgery and non-surgery group (P = 0.046) as well as in R0 resection and R1&R2 resection group (P = 0.045) were significant, respectively. DISCUSSION: Our study identified that chemoimmunotherapy plus surgery could improve overall survival in resectable ESCC, and patients had significant benefits from surgery and R0 tumor resection.
trial registrationTD-NICE study was registered in the August 28, 2020, and the registration number was ChiCTR2000037488 (Chinese Clinical Trial Registry (ChiCTR) identifier).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.